Founded in 2024 through the combination of BIOVIAN and 3P Biopharmaceuticals, two leading CDMO with a solid track record in the biotech and advanced therapies industries, 3PBIOVIAN was created to offer comprehensive and innovative solutions to clients across the global biopharmaceutical landscape.
With two manufacturing plants located in Noáin (Navarre) and Turku (Finland), 3PBIOVIAN offers a full spectrum of capabilities to meet the diverse process development and manufacturing needs of new medicines for its clients: from recombinant proteins and monoclonal antibodies to plasmids and advanced therapies.
The company views this first year as a period of learning, growth, and expansion. In just 12 months, 3PBIOVIAN has gained the trust of numerous new clients who have selected the company as their ideal partner for both protein and advanced therapy projects, while also strengthening its relationships with long-time collaborators. This growth has positioned 3PBIOVIAN as a key player in the global development of new medicines for the biotechnology industry.
Driving the company’s growth is a team of more than 500 highly skilled professionals working at both locations. In the words of Dámaso Molero, CEO of 3PBIOVIAN, “The true strength of our company lies in our people, who have worked tirelessly to create an environment of excellence focused on the customer and their manufacturing needs. We are deeply grateful to everyone who has contributed to our success.“
Challenges and Future Goals
Looking ahead, 3PBIOVIAN is committed to continuing its mission of helping clients in the development and manufacturing of therapies that will transform the medicine of tomorrow.
To achieve this, the company has a strategic investment plan for the coming years aimed at addressing the challenges of the competitive industry in which it operates. This includes reinforcing and expanding the capabilities of its business lines – proteins and advanced therapies – expanding its offerings to the United States, and consolidating itself as a leading CDMO in the market.